6:55 am BioCryst Pharm beats Q2 estimates including RAPIVAB licensing deal (BCRX) :

• Reports Q2 (Jun) earnings of $0.07 per share, $0.33 better than the Capital IQ Consensus of ($0.26); revenues rose 1620.0% year/year to $25.8 mln vs the $3.84 mln consensus. 
• Revenue in the quarter was primarily due to the partial recognition of the upfront payment to BioCryst resulting from the licensing of RAPIVAB (peramivir injection), as well as a significant increase in collaboration revenue associated with BCX4430 development as a medical countermeasure for Ebola virus and other filovirus diseases. 
• Update/Outlook: 
• The Phase 1 healthy volunteer study of BCX7353 initiated in May is continuing toward completion. In order to properly characterize the steady state pharmacokinetics of BCX7353, a 14 day treatment cohort will be added to this study. 
• As a consequence, final results of this study are now expected in the fourth quarter. BioCryst anticipates reporting results for safety, tolerability, pharmacokinetics and pharmacodynamics. 
• The OPuS-2 (Oral ProphylaxiS-2) clinical trial is proceeding as planned, and BioCryst expects to report results at the end of 2015. Based upon development plans and assumptions and our awarded government contracts, 
• BioCryst expects its 2015 net operating cash use to be in the range of $18 to $28 million upon adjusting our previously predicted range for the first six month results, including the $33.7 million upfront payment from bioCSL, and expects its 2015 operating expenses to continue to be in the range of $75 to $95 million.

6:42 am New York REIT announced its support of the acquisition of AR Capital LLC, the parent of its sponsor, and Apollo Global Management (APO) (NYRT) :  

6:42 am LSB Industries misses by $0.35, misses on revs; LSB to implement strategic, operational and corporate governance enhancements (LXU) :

• Reports Q2 (Jun) earnings of $0.02 per share, $0.35 worse than the Capital IQ Consensus Estimate of $0.37; revenues fell 9.4% year/year to $182.7 mln vs the $195.99 mln consensus. 
• As a result of the Strategic Committee's report, the Company's Board of Directors has determined the following: 
• LSB will establish an Operations Oversight Committee of the Board to foster more direct interaction between the members of the Board and senior management in management's execution of the Company's business strategy over the next 18 to 24 months. The committee will focus on management's execution of near-term business objectives and advise management on preserving strategic optionality to enhance shareholder value. 
• LSB will engage the services of an independent consultant to review the operations of the Climate Control business with a specific focus on driving higher margins.

6:35 am Enerplus reports Q2 (Jun) results (ERF) : Reports Q2 (Jun) loss of $1.52 per share, may not be comparable to the Capital IQ Consensus Estimate of $0.06. 

• Production volumes grew by 7% quarter over quarter to 107,429 BOE per day. This growth was primarily driven by increased activity in North Dakota, where production averaged approximately 27,100 BOE per day, up over 25% from the first quarter of 2015. 
• "We delivered another quarter of strong operating results. On the back of this operational momentum and improved cost efficiencies, we are increasing our 2015 production guidance and reducing our operating and G&A expense guidance.We continue to navigate through this challenging commodity price environment with a strong balance sheet and hedging program that will support our funds flow."
  

6:33 am Sirona Dental Systems beats by $0.01, beats on revs; reaffirms FY15 guidance (SIRO) : Reports Q3 (Jun) earnings of $1.16 per share, $0.01 better than the Capital IQ Consensus Estimate of $1.15; revenues rose 2.1% year/year to $306.1 mln vs the $295.71 mln consensus.

•  Co reaffirms guidance for FY15, sees EPS of $3.95-4.05 vs. $3.99 Capital IQ Consensus Estimate; reiterates guidance of FY15 organic local currency revenue growth of 6% to 8%.
  

6:31 am DepoMed sends an open letter to Horizon Pharmaceuticals (HZNP): confirms receipt of a proposal increase that includes a cash component (DEPO) : Co's letter stated:

• "In our conversation late last week, you stated that Horizon (HZNP) was prepared to increase its proposal and to include a cash component of up to 25%. This was confirmed in an email late Friday night from one of your Board members to our Board Chairman. Yet you still have not made a new proposal. Instead, you have insisted that we need to first make a counter-offer. It does not make any sense to engage with Horizon unless you make a sufficiently compelling and detailed proposal. 
• You continue to be wrongly focused on a "premium to unaffected price", when you know that our so-called "unaffected price" did not take account of our recent strong results. What matters is the intrinsic value of Depomed and the contribution Depomed would make to the combined company. 
• Our Board takes its fiduciary duties seriously and will always be open to any compelling proposal that creates value for its shareholders, but we are prepared and committed to take actions that we deem appropriate to protect our shareholders' interests, even if it involves protracted litigation and a proxy fight."
  

6:30 am Glori Energy reports in-line Q2 results (GLRI) :

• Adj. EBITDA for Q2 was a negative $1.5 mln, in-line with estimates, compared to a negative $857,000 for the second quarter of 2014. 
• Total revenues for the second quarter of 2015 were $2.6 mln vs. 2.6 mln single est, down from $5.6 million in the prior-year period due to the significant decline in oil prices and due to the completion, and recognition of revenues, on a large customer project that contributed $1.5 million in revenues in the second quarter of 2014. 
• "I am excited that implementation has now begun in the Coke Field. We expect to see a reversal of the natural production decline in the portion of the field affected by the first AERO injector over the next two to four months, followed by a gradual uplift in production over the next several months. We look forward to obtaining this important field and production data and communicating our results.
  

6:23 am Digirad reports Q2 EPS of $0.06 vs $0.06 year ago; revs 6.2% y/y to $15.5 mln (no estimates); Confirms financial guidance for 2015 (DRAD) :

• As previously announced, the Company's 2015 financial guidance is to generate revenues between $61.0 mln and $63.0 mln; non-GAAP adjusted diluted earnings per share between $0.19 and $0.21; and non-GAAP adjusted EBITDA between $6.5 mln and $6.9 mln.
  

6:20 am JD.com beats by RMB 0.12, beats on revs; guides Q3 revs in-line (JD) :

• Reports Q2 (Jun) loss of RMB 0.01 per share, excluding non-recurring items, RMB 0.12 better than the Capital IQ Consensus of (RMB 0.13); revenues rose 60.5% year/year to RMB 45.93 bln vs the RMB 44.43 bln consensus. 
• GMV for Q2 was RMB114.5 billion (US$18.5 billion), an increase of 82% compared with the second quarter of 2014. JD Mall GMV for the second quarter of 2015 increased by 92% year-over-year. 
• Co issues in-line guidance for Q3, sees Q3 revs of RMB 43.2-44.7 bln vs. RMB 44.14 bln Capital IQ Consensus Estimate.
  

6:18 am Thompson Creek Metals last night reported Q2 results; misses on EPS by $0.04, misses on revs (TC) : Reports Q2 (Jun) loss of $0.06 per share, $0.05 worse than the Capital IQ Consensus Estimate of ($0.01); revenues fell 46.0% year/year to $134.1 mln vs the $137.8 mln consensus. 

• Sales volumes and average realized sales prices for copper and gold for the second quarter of 2015 were 21.2 million pounds of copper at an average realized price of $2.63 per pound and 57,920 ounces of gold at an average realized price of $975 per ounce.
  

6:13 am Hill-Rom beats by $0.01, beats on revs; guides Q4 EPS in-line, revs above consensus (HRC) : Reports Q3 (Jun) earnings of $0.62 per share, $0.01 better than the Capital IQ Consensus Estimate of $0.61; revenues rose 19.3% year/year to $474.5 mln vs the $451.63 mln consensus.

• Co issues guidance for Q4, sees EPS of $0.76-0.79 vs. $0.78 Capital IQ Consensus Estimate; sees Q4 revs of +1-3% to ~$484.6-494.2 mln vs. $480.89 mln Capital IQ Consensus Estimate. 
• Hill-Rom now expects cash flow from operations for the full year to be ~$235 mln, compared to $250 mln previously. Capital expenditures are now expected to be $125 mln, compared to $140 mln previously.
  

6:11 am Telus reports EPS in-line, revs in-line; reaffirms FY15 EPS guidance (TU) : Reports Q2 (Jun) earnings of CC$0.66 per share, in-line with the Capital IQ Consensus Estimate of CC$0.66; revenues rose 5.1% year/year to CC$3.1 bln vs the CC$3.08 bln consensus.

• Wireless network revenues increased by $90 million or 6.1 per cent to $1.57 billion in the second quarter of 2015, when compared to the same period a year ago. 
• This growth was driven by an 18 per cent increase in data revenue, reflecting subscriber growth, increased proportion of higher-rate two-year plans in the subscriber mix, higher data usage from a continued adoption of smartphones and other data-centric devices, increased data roaming and the expansion of TELUS' LTE network coverage. 
• Blended ARPU increased by 2.9 per cent to $63.48, reflecting TELUS' nineteenth consecutive quarter of year-over-year growth.
  

• TELUS now anticipates full year consolidated capital expenditures of approximately $2.5 billion compared to its previously estimated 2015 target of 'similar to 2014' ($2.359 billion).
  

6:06 am Universal American Corp misses by $0.04, misses on revs (UAM) : Reports Q2 (Jun) earnings of $0.02 per share, excluding non-recurring items, $0.04 worse than the Capital IQ Consensus Estimate of $0.06; revenues fell 9.8% year/year to $416.3 mln vs the $465.88 mln consensus.

6:05 am HMS Holdings reports EPS in-line, beats on revs (HMSY) : Reports Q2 (Jun) earnings of $0.13 per share, excluding non-recurring items, in-line with the Capital IQ Consensus Estimate of $0.13; revenues rose 3.8% year/year to $116.9 mln vs the $115.01 mln consensus. 

• Payment integrity revenue in 2q, excluding medicare RAC, increased 9% YoY
• Medicaid coordination of benefits revenue in Q2 increased 7% YoY
  

6:02 am Himax Tech reports EPS in-line, misses on revs; guides Q3 EPS below consensus, revs below consensus (HIMX) : Reports Q2 (Jun) Non-GAAP per ADS earnings of $0.05 per share, in-line with the Capital IQ Consensus Estimate of $0.05; revenues fell 13.8% year/year to $169.2 mln vs the $173.62 mln consensus.

• Co issues downside guidance for Q3, sees EPS Non-GAAP per ADS of $0.01-0.016 vs. $0.07 Capital IQ Consensus Estimate; sees Q3 revs of decline of 5-9% QoQ to ~$153.9-160.7 mln vs. $205.28 mln Capital IQ Consensus Estimate; sees gross margin down 1.5% from Q2.
• GAAP gross margin for the second quarter of 2015 was 23.8%, a 40 basis points decrease from 24.2% in the same period last year.

6:01 am Baker Hughes announces July 2015 rig counts with avg US rig count of 866 (BHI) : Co reported:

• The international rig count for July 2015 was 1,118, down 28 from 1,146 M/M
• The international offshore rig count for July 2015 was 264, down 13 from 277 M/M
• The average U.S. rig count for July 2015 was 866, up 5 from 861 M/M

6:00 am HMS Holdings announces Board authorization for a $75 million share repurchase program (HMSY) :  

5:59 am S&P futures vs fair value: -1.10. Nasdaq futures vs fair value: -4.80. :

5:59 am European Markets : FTSE...6747.23...+0.10...0.00.  DAX...11571.44...-13.70...-0.10%.

5:59 am Asian Markets : Nikkei...20724.56...+60.10...+0.30%.  Hang Seng...24552.47...+177.20...+0.70%.

5:09 am Magna beats by $0.11, reports revs in-line; guides FY15 revs in-line (MGA) : Reports Q2 (Jun) earnings of $1.29 per share, $0.11 better than the Capital IQ Consensus Estimate of $1.18; revenues fell 8.7% year/year to $8.13 bln vs the $8.07 bln consensus.

Guidance
Co issues in-line guidance for FY15, sees FY15 revs of $30.9-32.6 bln vs. $32.34 bln Capital IQ Consensus Estimate.

• Co sess FY15 Capital Spending: $1.3-1.5 bln